Drug
Savolitinib
Savolitinib: highest development phase Phase 3, developed by Hutchmed, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Hutchmed, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Savolitinib NCT04923945 | Phase 3 | Non-small Cell Lung Cancer Metastatic |
| Savolitinib NCT05009836 | Phase 3 | Non-small Cell Lung Cancer |
| Savolitinib NCT02897479 | Phase 2 | Lung Sarcomatoid Carcinoma |
| Savolitinib NCT04923932 | Phase 2 | Gastric Cancer |
Latest
No recent events.
Follow Savolitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.